Grace Therapeutics (GRCE) 10% Owner Inc. Buys $41K of Stock
Key Points
- Opaleye Management now holds about 2.97 million shares of Grace Therapeutics after this latest purchase, which is a 0.73% increase in its holdings.
- After the trade, Opaleye Management Inc. indirectly holds 2,970,000 $GRCE shares, up 0.73% from before the trade.
- The stock closed at $1.92 on the day of the transaction, while it recently traded around $1.81, which is about 5.7% below that closing price.
- Grace Therapeutics has a market cap of about $40.6 million and trades significantly below its 52-week high of $5.18.
Since the trade, $GRCE is down 5.7% to date (from the $1.92 close on Oct 22, 2026).
Get Grace Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $GRCE.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Grace Therapeutics, Inc. alert may contain errors. Disclosures
On October 22, 2026, Opaleye Management Inc., a 10% owner of Grace Therapeutics, Inc. (GRCE), bought 21,390 shares for about $41,193. This transaction was reported in a Form 4 filing with the SEC. After this purchase, Opaleye now holds approximately 2.97 million shares of the company, reflecting a 0.73% increase in its position.
Opaleye's recent activity is part of a series of purchases it made in October. Earlier, on October 16, it acquired 36,347 shares at an average price of $1.89, followed by smaller buys on October 9, 12, and 15. This consistent buying trend indicates a growing confidence in Grace Therapeutics' future.
GRCE
Grace Therapeutics, Inc.
Opaleye Management Inc. vs. the S&P 500
Hypothetical returns from Opaleye Management Inc.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Grace Therapeutics
Several other institutions have also been involved with Grace Therapeutics recently. Cerity Partners LLC held 849,055 shares, while Eversept Partners, LP increased its stake by 16,268 shares to reach 772,900 shares. Citadel Advisors LLC added 250,999 shares, bringing its total to 349,740. Maven Securities Limited grew its holdings by 100,000 shares, now owning 200,000 shares. Birchview Capital, LP also increased its stake by 70,000 shares, totaling 120,000 shares.
Grace Therapeutics, Inc. Stock Down 5.5%
On October 22, Grace Therapeutics closed at $1.92. The stock has been trading below its 50-day moving average of $2.10 and its 200-day moving average of $2.86. Recently, it traded around $1.81, which is about 5.7% below its closing price on the event date. Additionally, the stock is approximately 65.1% below its 52-week high of $5.18, indicating challenges in gaining investor confidence.
Recent Earnings
Grace Therapeutics reported trailing twelve-month revenue of $0, and its earnings per share (EPS) is at -$1.17. The company has not yet turned a profit, reflected in its negative return on equity of -36.2%. The next earnings report is expected on November 15, 2026.
Insider Buying and Selling at Grace Therapeutics, Inc.
Opaleye Management has been active in acquiring shares of Grace Therapeutics in October. It bought 5,340 shares on October 9 for about $10,918, followed by 7,215 shares on October 12 valued at $14,574. On October 15, it purchased 23,485 shares for about $45,685 and then the 21,390 shares on October 22. These transactions show a pattern of increasing investment in the company.
Analysts Set New Price Targets
Currently, there are no new analyst ratings or price targets for Grace Therapeutics. The average target price remains $5.96, which is significantly higher than the current trading price, suggesting potential upside if the company can improve its financial performance.
About Grace Therapeutics
Grace Therapeutics, Inc. is focused on developing and commercializing pharmaceutical products aimed at treating rare and orphan diseases in Canada. Its leading candidate is GTX-104, designed for treating aneurysmal subarachnoid hemorrhage. The company is headquartered in Princeton, NJ, and has a small team of five employees.
Bottom Line
Investors should watch for Grace Therapeutics' next earnings report on November 15, 2026, to see if the company can begin generating revenue. Opaleye Management's continued buying suggests it sees potential in Grace, but the stock's performance relative to its historical highs raises questions about its future trajectory.
Related Filing Alerts
Source: Opaleye Management Inc.'s Form 4 filing on $GRCE (Oct 22, 2026). Written by software, not financial advice. How we make alerts